Anavex Life Sciences Corp.
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
About
CEO
Dr. Christopher U. Missling M.B.A., M.S., Ph.D.
Employees
40
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNGS
Address
630 5th Avenue, New York, NY 10111, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Dec 22, 2025 | — | — | — | — |
| Aug 4, 2025 | — | — | — | — |
| May 7, 2025 | — | — | — | — |
| Feb 5, 2025 | — | — | — | — |
| Dec 23, 2024 | -0.16 | -0.14 | 0.02 | -12.50% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Current Year
(Sep 2025)
|
Next Year
(Sep 2026)
|
||
|---|---|---|---|---|
| Number of analysts | — | 1 | 2 | 1 |
| Average estimate | — | -0.18 | -0.65 | 5.11 |
| Low estimate | — | -0.18 | -0.73 | 5.11 |
| High estimate | — | -0.18 | -0.56 | 5.11 |
| Last year EPS | — | -0.13 | -0.52 | -0.65 |
[stock_revenue_estimate]
Growth estimates
Current qtr
-54.550%
Next qtr. (Mar 2025)
-38.460%
Current year (Sep 2025)
-24.040%
Next year (Sep 2026)
892.250%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Fiscal date | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 |
| Total reported revenue | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating expense | |||||
| Research & development | 41.84M | 43.72M | 37.92M | 32.98M | 25.23M |
| Selling general and admin | 11.04M | 12.04M | 13.07M | 9.02M | 5.86M |
| Other operating expenses | -75,000 | -25,000 | — | -54,000 | -149,888 |
| Operating income | -52.80M | -55.73M | -50.99M | -41.95M | -30.94M |
| Non operating interest income | |||||
| Income | 7.32M | 6.52M | 947,000 | 26,000 | 179,973 |
| Expense | — | 964,000 | — | — | — |
| Other income expense | 2.48M | 2.68M | 2.42M | 4.28M | 4.50M |
| Pretax income | -43.00M | -47.50M | -47.62M | -37.64M | -26.26M |
| Tax provision | — | 7,000 | 358,000 | 268,000 | 22,664 |
| Net income | -43.00M | -47.51M | -47.98M | -37.91M | -26.28M |
| Basic EPS | — | -0.60 | -0.62 | -0.54 | -0.45 |
| Diluted EPS | — | -0.60 | -0.62 | -0.54 | -0.45 |
| Basic average shares | — | 79.79M | 76.91M | 69.80M | 58.19M |
| Diluted average shares | — | 79.79M | 76.91M | 69.80M | 58.19M |
| EBITDA | -43.19M | -46.49M | -46.72M | -37.38M | -31.06M |
| Net income from continuing op. | -43.00M | -47.51M | -47.98M | -37.91M | -26.28M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Fiscal date | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 |
| Total assets | 135.57M | 154.39M | 152.71M | 161.62M | 34.54M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 132.19M | 151.02M | 149.16M | 152.11M | 29.25M |
| Other short term investments | — | — | — | — | — |
| Accounts receivable | — | — | — | — | — |
| Other receivables | — | — | — | — | — |
| Inventory | — | — | — | — | — |
| Prepaid assets | — | — | 354,162 | 371,914 | 443,839 |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 931,000 | 653,000 | 354,000 | 371,914 | — |
| Non current assets | |||||
| Properties | — | — | — | — | — |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | — | — | — | — | — |
| Construction in progress | — | — | — | — | — |
| Leases | — | — | — | — | — |
| Accumulated depreciation | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Investments and advances | — | — | — | — | — |
| Other non current assets | — | — | — | — | — |
| Total liabilities | 15.30M | 12.53M | 10.21M | 10.80M | 7.31M |
| Current liabilities | |||||
| Accounts payable | 9.63M | 4.32M | 3.83M | 4.74M | 3.99M |
| Accrued expenses | 3.31M | 5.94M | 4.65M | 4.41M | 2.75M |
| Short term debt | — | — | — | — | — |
| Deferred revenue | 842,000 | 917,000 | 444,000 | 443,831 | — |
| Tax payable | — | — | — | — | — |
| Pensions | 1.53M | 1.36M | 1.30M | 1.20M | 567,805 |
| Other current liabilities | — | — | — | — | — |
| Non current liabilities | |||||
| Long term debt | — | — | — | — | — |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | — | — | — | — | — |
| Shareholders equity | |||||
| Common stock | 85,000 | 82,000 | 78,000 | 75,920 | 62,047 |
| Retained earnings | -336.07M | -293.07M | -245.56M | -197.59M | -159.68M |
| Other shareholders equity | — | — | — | — | — |
| Total shareholders equity | 120.26M | 141.85M | 142.49M | 150.82M | 27.24M |
| Additional paid in capital | 456.25M | 434.84M | 387.98M | 348.33M | 186.85M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||||||||
| Net Income | -43.00M | -47.51M | -47.98M | -37.91M | -26.28M | -26.29M | -17.25M | -13.46M | -14.74M | -12.11M | -9.97M | -3.70M | -8.30M | -7.31M | -8.78M | -5.50M | -5.35M | -1.58M | -25,532 | -91,625 | -14,395 |
| Depreciation | — | — | — | — | — | — | — | — | 1,252 | 995 | 768 | 576 | 1,858 | 1,657 | 910 | 410 | 220 | — | — | — | — |
| Deferred Taxes | — | — | — | — | — | — | — | — | — | — | -1.40M | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 9.44M | 16.37M | 18.38M | 8.23M | 4.88M | 6.43M | 5.52M | 4.14M | 5.06M | 1.63M | 637,925 | 1.00M | 302,208 | 1.27M | 770,055 | 812,336 | — | — | — | — | — |
| Other Non-Cash Items | — | 845,000 | — | — | — | 35,375 | — | -75,204 | -145,572 | 4.54M | 2.84M | 978,095 | 251,375 | -30,581 | -6.32M | 1.10M | 2.42M | 800,000 | — | — | — |
| Accounts Receivable | 260,000 | 484,000 | 5.94M | -4.29M | -2.21M | -772,388 | -231,096 | 54,435 | -2,507 | -76,840 | — | — | 809 | 37,011 | -37,820 | — | — | — | — | — | — |
| Accounts Payable | 5.31M | 497,000 | -914,000 | 751,000 | 465,722 | 683,797 | 38,233 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Assets & Liabilities | -75,000 | 473,000 | — | 444,000 | — | — | — | -70,532 | -1,082 | 71,614 | — | — | — | — | -511,844 | -927,469 | — | — | — | — | — |
| Operating Cash Flow | -28.07M | -28.84M | -24.57M | -32.77M | -23.14M | -19.92M | -11.93M | -9.42M | -9.82M | -5.93M | -7.89M | -1.72M | -7.75M | -6.03M | -14.88M | -4.52M | -2.93M | -779,993 | -25,532 | -91,625 | -14,395 |
| Investing Activities | |||||||||||||||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — | — | — | -3,015 | — | — | — | -3,310 | -1,239 | -1,082 | — | — | — | — |
| Net Intangibles | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Sale of Investments | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Investing Cash Flow | — | — | — | — | — | — | — | — | — | — | -3,015 | — | — | — | -3,310 | -1,239 | -1,082 | — | — | — | — |
| Financing Activities | |||||||||||||||||||||
| Long-Term Debt Issuance | — | — | — | — | — | — | — | — | — | — | 10.00M | — | — | — | 1.42M | 1.20M | — | — | — | — | — |
| Long-Term Debt Payments | — | — | — | — | — | — | — | — | -34,759 | -88,144 | — | — | — | — | — | — | — | — | — | — | — |
| Other Financing Charges | — | — | -707,000 | -5.55M | -403,764 | -50,000 | -101,133 | — | — | — | -788,712 | 60,000 | -8,150 | -100,000 | — | 300,000 | — | 313,000 | 23,726 | 9,939 | — |
| Financing Cash Flow | 11.28M | 27.88M | 20.28M | 147.67M | 28.35M | 17.78M | 8.07M | 27.27M | 3.10M | 12.17M | 9.58M | 1.11M | 1.57M | 3.67M | 4.51M | 4.34M | 1.13M | 313,000 | 23,726 | 33,939 | 40,000 |
| Other Cash Details | |||||||||||||||||||||
| End Cash Position | 132.19M | 151.02M | 149.16M | 152.11M | 29.25M | 22.19M | 22.93M | 27.44M | 9.19M | 15.29M | 7.26M | 345,074 | 11,362 | 134,702 | 264,669 | 350,994 | 6,357 | 25 | 12,275 | 977 | 28,110 |
| Income Tax Paid | 300,000 | 136,000 | 327,000 | 140,000 | 22,664 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | -30.81M | -27.79M | -24.24M | -30.38M | -21.29M | -18.53M | -12.58M | -9.02M | -9.24M | -4.23M | -2.66M | -777,573 | -1.69M | -3.80M | -4.60M | -2.80M | -2.48M | -325,250 | -32,428 | -61,072 | -11,890 |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 2,534,500 | 22.66M | 2.99% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 2,111,120 | 18.87M | 2.49% |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | Nov 30, 2024 | 1,523,919 | 13.62M | 1.80% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 1,331,918 | 11.91M | 1.57% |
| Fidelity Small Cap Index Fund | Oct 31, 2024 | 765,233 | 6.84M | 0.90% |
| iShares Biotechnology ETF | Nov 30, 2024 | 565,129 | 5.05M | 0.67% |
| iShares Russell 2000 Value ETF | Nov 30, 2024 | 538,737 | 4.82M | 0.64% |
| Fidelity Extended Market Index Fund | Nov 30, 2024 | 467,426 | 4.18M | 0.55% |
| Schwab Strategic Tr-Schwab U.S. Small Cap ETF | Nov 30, 2024 | 408,593 | 3.65M | 0.48% |
| Vanguard Russell 2000 Index Fund | Nov 30, 2024 | 351,382 | 3.14M | 0.41% |
Article
Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025
Webcast and Conference Call To be Held Wednesday, February 12, 2025, 8:30 am ET Webcast and Conference Call To be Held Wednesday, February 12, 2025, 8:30 am ET
Feb 5, 2025
Article
Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio
NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, announced today it was issued a new U.S. Patent No. 12,180,174 entitled “A2-73 CRYSTALLINE POLYMORPH COMPOSITIONS OF MATTER AND METHODS OF USE THEREOF” from the United States Patent and Trademark Office (USPTO) for its U.S. Patent Application Serial Number USSN: 17/978,818.
Jan 27, 2025
Article
Anavex Life Sciences Stock Skyrockets 95% in 3 Months: Here's Why
AVXL stock soars 95% in three months on positive updates from the development programs of its two clinical candidates, blarcamesine and ANAVEX 3-71.
Jan 24, 2025
